Tumour-selective drug delivery via folate receptor-targeted liposomes.
Tumour-selective drug delivery via folate receptor-targeted liposomes.
复制标题
DOI：
10.1517/17425247.1.1.7
复制
发表时间：
2004-11-01
影响因子：
6.6
通讯作者：
Lee, Robert J
中科院分区：
文献类型：
--
作者：
Pan, Xiaogang;Lee, Robert J
肿瘤细胞靶向脂质体递送具有提高治疗效果和降低抗癌药物毒性的潜力。叶酸受体（FR）的表达在人类恶性肿瘤中经常扩增。因此，FR作为靶向给药的肿瘤标志物具有潜在的用途。fr介导的脂质体递送已被证明可以增强阿霉素的体外和体内抗肿瘤功效，并克服p -糖蛋白介导的多药耐药。此外，FR靶向脂质体已显示出作为基因和反义寡脱氧核糖核苷酸到FR（+）肿瘤细胞的有效递送载体的效用。实体瘤和白血病都可能从fr靶向药物递送中获益。多种机制可能有助于提高fr靶向脂质体的治疗效果，例如fr依赖的细胞毒性和抗血管生成活性。显然有必要进一步研究这种有前途的给药策略。
Tumour cell-targeted liposomal delivery has the potential to enhance the therapeutic efficacy and reduce the toxicity of anticancer agents. Folate receptor (FR) expression is frequently amplified among human malignancies. FR is, therefore, potentially useful as a tumour marker for targeted drug delivery. FR-mediated liposomal delivery has been shown to enhance the antitumour efficacy of doxorubicin both in vitro and in vivo, and to overcome P-glycoprotein-mediated multi-drug resistance. In addition, FR-targeted liposomes have shown utility as effective delivery vehicles of genes and antisense oligodeoxyribonucleotides to FR(+) tumour cells. Both solid tumours and leukaemias can potentially benefit from FR-targeted drug delivery. Multiple mechanisms might contribute to greater therapeutic efficacy for FR-targeted liposomes, such as FR-dependent cytotoxicity and antiangiogenic activity. Further investigation of this promising drug delivery strategy is clearly warranted.